These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 7879133

  • 1. Impact of HLA matching, type of crossmatch, and immunosuppressive therapy on primary pediatric cadaver renal allograft survival.
    Kerman RH, Sullivan EK, Tejani A.
    Transplant Proc; 1995 Feb; 27(1):656-7. PubMed ID: 7879133
    [No Abstract] [Full Text] [Related]

  • 2. Living related donor kidney transplantation in patients with a positive flow cytometry crossmatch.
    Hong JH, Sadeghian M, Sumrani N, Distant DA, Sommer BG, Norin AJ.
    Transplant Proc; 1996 Jun; 28(3):1614-5. PubMed ID: 8658808
    [No Abstract] [Full Text] [Related]

  • 3. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months.
    Banowsky LH, Wright FH, Kothmann R, Floyd M, Vick S.
    Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K, Munn SR, Sterioff S.
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract] [Full Text] [Related]

  • 5. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N, Hong JH, DiBenedetto A, Clayton R, Miles AM, Markell MS, Distant DA, Fleishhacker J, Sommer BG.
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract] [Full Text] [Related]

  • 6. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation.
    Abouna GM, Kumar MS, Stephan R, Prior JE, Lyons P, Bulova SI, al-Abdullah IH.
    Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886
    [No Abstract] [Full Text] [Related]

  • 7. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
    Chen M, Wade J, Levy GA, Greig PD.
    Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
    [No Abstract] [Full Text] [Related]

  • 8. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 9. Rapidly rising pretransplant hematocrit and hematocrit > or = 30% signal independent risks for delayed function and primary nonfunction in primary cadaveric renal transplantation.
    Schmidt R, Kupin W, Dumler F, Venkat KK, Mozes M.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1064-5. PubMed ID: 8442044
    [No Abstract] [Full Text] [Related]

  • 10. Strategy for improving retransplantation in the CyA era.
    Dickerman R, Langley J, Brinker K, Trevino G, Melton L, Vergne-Marini P, Wilson PK.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract] [Full Text] [Related]

  • 11. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M, Taddei C, Nguyen JM, Dantal J, Hourmant M, Cantarovich D, Blancho G, Ancelet D, Soulillou JP.
    Clin Transpl; 1996 Feb; ():257-64. PubMed ID: 9286575
    [Abstract] [Full Text] [Related]

  • 12. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF, Venkat KK, Kupin W, Dumler F, Gracida C, Uniewski M, Anaise D, Tang DH.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract] [Full Text] [Related]

  • 13. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES, Thistlethwaite JR, Haas M, Josephson MA, Newell KA, Bruce DS, Millis JM, Piper JB, Charette JI.
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract] [Full Text] [Related]

  • 14. Delayed graft function of cadaveric renal transplants is prevented by diltiazem.
    Carmellini M, Salvadori M, Di Stefano R, Bertoni E, Nicita G, Rosati A, Taddei G, Rindi P, Rizzo G, Mosca F.
    Transplant Proc; 1996 Feb; 28(1):80-2. PubMed ID: 8644348
    [No Abstract] [Full Text] [Related]

  • 15. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS, Ibrahim H, Tolman D, Kirchberg D, Salter D, Guerraty A, Mohanty PK.
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract] [Full Text] [Related]

  • 16. Prospective randomized study of quadruple versus triple therapy in long-term kidney allografts.
    Fruchaud G, Buisson C, Abbou C, Desvaux D, Baron C, Benmaadi A, Chopin D, Bourgeon B, Dahmane D, Rostoker G, Weil B, Lang P.
    Transplant Proc; 1996 Oct; 28(5):2819. PubMed ID: 8908077
    [No Abstract] [Full Text] [Related]

  • 17. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM, Sánchez J, García J, Puig N, Sánchez P, Górriz JL, Cruz JM.
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
    Taylor CJ, Bayne AM, Welsh KI, Morris PJ.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):210-1. PubMed ID: 8438273
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.